Cargando…

Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss

Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition...

Descripción completa

Detalles Bibliográficos
Autores principales: Straznicky, Nora E., Grima, Mariee T., Sari, Carolina I., Lambert, Elisabeth A., Phillips, Sarah E., Eikelis, Nina, Mariani, Justin A., Kobayashi, Daisuke, Hering, Dagmara, Dixon, John B., Lambert, Gavin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093133/
https://www.ncbi.nlm.nih.gov/pubmed/27857694
http://dx.doi.org/10.3389/fphys.2016.00516
_version_ 1782464852953923584
author Straznicky, Nora E.
Grima, Mariee T.
Sari, Carolina I.
Lambert, Elisabeth A.
Phillips, Sarah E.
Eikelis, Nina
Mariani, Justin A.
Kobayashi, Daisuke
Hering, Dagmara
Dixon, John B.
Lambert, Gavin W.
author_facet Straznicky, Nora E.
Grima, Mariee T.
Sari, Carolina I.
Lambert, Elisabeth A.
Phillips, Sarah E.
Eikelis, Nina
Mariani, Justin A.
Kobayashi, Daisuke
Hering, Dagmara
Dixon, John B.
Lambert, Gavin W.
author_sort Straznicky, Nora E.
collection PubMed
description Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition attained following equivalent dietary weight loss. Methods: Un-medicated obese individuals categorized as normal glucose tolerant (NGT, n = 15), impaired glucose tolerant (IGT, n = 24), and newly-diagnosed T2D (n = 15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for 4-months. The three groups were matched for baseline age (56 ± 1 years), body mass index (BMI, 32.9 ± 0.7 kg/m(2)), and gender. Clinical measurements included whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by microneurography), spontaneous cardiac baroreflex sensitivity (BRS), and oral glucose tolerance test. Results: Weight loss averaged −7.5 ± 0.8, −8.1 ± 0.5, and −8.0 ± 0.9% of body weight in NGT, IGT, and T2D groups, respectively. T2D subjects had significantly greater reductions in fasting glucose, 2-h glucose and glucose area under the curve (AUC(0−120)) compared to NGT and IGT (group effect, P <0.001). Insulinogenic index decreased in IGT and NGT groups and increased in T2D (group × time, P = 0.04). The magnitude of reduction in MSNA (−7 ± 3, −8 ± 4, −15 ± 4 burst/100 hb, respectively) and whole-body norepinephrine spillover rate (−28 ± 8, −18 ± 6, and −25 ± 7%, respectively), time effect both P <0.001, did not differ between groups. After adjustment for age and change in body weight, Δ insulin AUC(0−120) was independently associated with reduction in arterial norepinephrine concentration, whilst Δ LDL-cholesterol and improvement in BRS were independently associated with decrease in MSNA. Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar sympathoinhibition in matched obese subjects with different baseline glucose tolerance. Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is associated with reduction in SNS activity following weight loss intervention.
format Online
Article
Text
id pubmed-5093133
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-50931332016-11-17 Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss Straznicky, Nora E. Grima, Mariee T. Sari, Carolina I. Lambert, Elisabeth A. Phillips, Sarah E. Eikelis, Nina Mariani, Justin A. Kobayashi, Daisuke Hering, Dagmara Dixon, John B. Lambert, Gavin W. Front Physiol Physiology Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition attained following equivalent dietary weight loss. Methods: Un-medicated obese individuals categorized as normal glucose tolerant (NGT, n = 15), impaired glucose tolerant (IGT, n = 24), and newly-diagnosed T2D (n = 15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for 4-months. The three groups were matched for baseline age (56 ± 1 years), body mass index (BMI, 32.9 ± 0.7 kg/m(2)), and gender. Clinical measurements included whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by microneurography), spontaneous cardiac baroreflex sensitivity (BRS), and oral glucose tolerance test. Results: Weight loss averaged −7.5 ± 0.8, −8.1 ± 0.5, and −8.0 ± 0.9% of body weight in NGT, IGT, and T2D groups, respectively. T2D subjects had significantly greater reductions in fasting glucose, 2-h glucose and glucose area under the curve (AUC(0−120)) compared to NGT and IGT (group effect, P <0.001). Insulinogenic index decreased in IGT and NGT groups and increased in T2D (group × time, P = 0.04). The magnitude of reduction in MSNA (−7 ± 3, −8 ± 4, −15 ± 4 burst/100 hb, respectively) and whole-body norepinephrine spillover rate (−28 ± 8, −18 ± 6, and −25 ± 7%, respectively), time effect both P <0.001, did not differ between groups. After adjustment for age and change in body weight, Δ insulin AUC(0−120) was independently associated with reduction in arterial norepinephrine concentration, whilst Δ LDL-cholesterol and improvement in BRS were independently associated with decrease in MSNA. Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar sympathoinhibition in matched obese subjects with different baseline glucose tolerance. Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is associated with reduction in SNS activity following weight loss intervention. Frontiers Media S.A. 2016-11-03 /pmc/articles/PMC5093133/ /pubmed/27857694 http://dx.doi.org/10.3389/fphys.2016.00516 Text en Copyright © 2016 Straznicky, Grima, Sari, Lambert, Phillips, Eikelis, Mariani, Kobayashi, Hering, Dixon and Lambert. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Straznicky, Nora E.
Grima, Mariee T.
Sari, Carolina I.
Lambert, Elisabeth A.
Phillips, Sarah E.
Eikelis, Nina
Mariani, Justin A.
Kobayashi, Daisuke
Hering, Dagmara
Dixon, John B.
Lambert, Gavin W.
Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title_full Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title_fullStr Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title_full_unstemmed Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title_short Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naïve Type 2 Diabetes following Equivalent Weight Loss
title_sort comparable attenuation of sympathetic nervous system activity in obese subjects with normal glucose tolerance, impaired glucose tolerance, and treatment naïve type 2 diabetes following equivalent weight loss
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5093133/
https://www.ncbi.nlm.nih.gov/pubmed/27857694
http://dx.doi.org/10.3389/fphys.2016.00516
work_keys_str_mv AT straznickynorae comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT grimamarieet comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT saricarolinai comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT lambertelisabetha comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT phillipssarahe comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT eikelisnina comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT marianijustina comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT kobayashidaisuke comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT heringdagmara comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT dixonjohnb comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss
AT lambertgavinw comparableattenuationofsympatheticnervoussystemactivityinobesesubjectswithnormalglucosetoleranceimpairedglucosetoleranceandtreatmentnaivetype2diabetesfollowingequivalentweightloss